The incidence of hospitalized cases of systemic mycotic infections

Hammerman, Kenneth J.; Powell, Kenneth E.; Tosh, Fred E.

doi:10.1080/00362177485380061

Cited by 51 publications

(15 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although information about the incidence of LS in the United States is limited, a few studies have estimated the annual incidence of sporotrichosis to be 0.2-2.4 cases per million persons [17][18][19][20]. Previously published reports from South Africa, India, and Japan suggest that S. schenckii may thrive in special ecological areas [12][13][14][15][16].…”

Section: Discussionmentioning

confidence: 99%

Population‐Based Surveillance and a Case‐Control Study of Risk Factors for Endemic Lymphocutaneous Sporotrichosis in Peru

et al. 2003

View full text Add to dashboard Cite

Population-based surveillance and a case-control study were conducted in Abancay, Peru, to estimate the burden of disease and to determine risk factors for sporadic lymphocutaneous sporotrichosis (LS). Laboratory records from local hospitals were reviewed for the years of 1997 and 1998, and prospective surveillance was conducted for the period of September 1998 through September 1999. A case-control study was conducted with 2 matched control subjects per case patient. The mean annual incidence was 98 cases per 100,000 persons. Children had an incidence 3 times higher than that for adults and were more likely to have LS lesions on the face and neck. Identified risk factors included owning a cat, playing in crop fields, having a dirt floor in the house, working mainly outdoors, and having a ceiling made of raw wood or conditions associated with a lower socioeconomic status. Decreased environmental exposure, such wearing protective clothing during construction activities for adults or limiting contact with cats and soil for children, and improvements in living spaces may decrease the incidence of LS.

show abstract

Section: Discussionmentioning

confidence: 99%

Population‐Based Surveillance and a Case‐Control Study of Risk Factors for Endemic Lymphocutaneous Sporotrichosis in Peru

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Nevertheless, estimates of over a half million infections by Histoplasma and Coccidioides occur each year. 29,30 Paracoccidioides and Blastomyces infection estimates are more difficult due to regional differences, however reports suggest the incidence ranges from 0.05 to 3 per 100,000 individuals in endemic regions. 23,[31][32][33] Together these 4 dimorphic fungal pathogens infect hundreds of thousands each year, a number which does not include veterinary infections.…”

Section: Dimorphism and Endemicitymentioning

confidence: 99%

Antifungal therapeutics for dimorphic fungal pathogens

Goughenour

Rappleye

2016

Virulence

View full text Add to dashboard Cite

Dimorphic fungi cause several endemic mycoses which range from subclinical respiratory infections to life-threatening systemic disease. Pathogenic-phase cells of Histoplasma, Blastomyces, Paracoccidioides and Coccidioides escape elimination by the innate immune response with control ultimately requiring activation of cell-mediated immunity. Clinical management of disease relies primarily on antifungal compounds; however, dimorphic fungal pathogens create a number of challenges for antifungal drug therapy. In addition to the drug toxicity issues known for current antifungals, barriers to efficient drug treatment of dimorphic fungal infections include natural resistance to the echinocandins, residence of fungal cells within immune cells, the requirement for systemic delivery of drugs, prolonged treatment times, potential for latent infections, and lack of optimized standardized methodology for in vitro testing of drug susceptibilities. This review will highlight recent advances, current therapeutic options, and new compounds on the horizon for treating infections by dimorphic fungal pathogens.

show abstract

“…Thus, temporal trends in the incidence of fungal infections are difficult to monitor. However, a previous study demonstrated that the incidence of systemic mycoses resulting in hospitalization had increased markedly in 1976, compared with the incidence in 1970 [1,2]. To see if this upward trend was continuing, we reviewed data from the Commission on Professional and Hospital Activities (CPHA) regarding hospitalizations for systemic mycoses in 1980-1982 and compared the results with those reported previously for 1970 and 1976.…”

Section: (Accepted 23 June 1986)mentioning

confidence: 83%